This document is a patent application publication from the European Patent Office (EPO) concerning a cancer therapy utilizing Capivasertib and Fulvestrant. The application, identified as EP4630002A1 and published on March 18, 2026, lists AstraZeneca AB as the applicant and details specific International Patent Classification (IPC) codes related to pharmaceutical compositions for treating cancer.

As this is a patent publication, it does not impose direct compliance obligations or deadlines on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in oncology research and development, as it pertains to intellectual property rights and potential future market exclusivity for specific therapeutic approaches.